FORBES PHARMACY SUBLOCADE REFERRAL

PHONE 412.246.6160 FAX 855.683.0160 EMAIL forbes_pharm@upmc.edu



In order to initiate Sublocade treatment, please send a valid prescription to Forbes Pharmacy along with a completed referral form.

REFERRAL SOURCE						
Name/Title of Person Completing Form:				Date:		
PATIENT INFORMATION						
Last Name: First N		lame:		DOB:	Sex: M F	Facility:
Address:			City:		State:	ZIP:
Cell Phone:	Home Phone:			Room/Unit N	lumber (Inpatient):	
Emergency Contact:		Phone Number:				
INJECTION PLAN						
Outpatient Injection		☐ CPCDS ☐ Magee ☐ Mercy ☐ NATP ☐ Other Clinic Contact (Name & Phone Number)				
One-Time Day of Discharge Injection		Location Follow-Up Clinic (Name & Phone Number)				
In accordance with the REMS, Sublocade injection may only be delivered to a healthcare setting and is never dispensed to a patient directly. Sublocade injection will only be used for the patient it is ordered and will NOT be transported to any other location/office/person.						
it is ordered	ana wi	II NOT be trans	ported t	o any other locatio	n/office/person.	
CLINICAL INFORMATION		·			· ,	
	- plea:	se include ap	plicabl	e clinical chart n	otes	tion:
CLINICAL INFORMATION	- <i>plea</i> st	se include ap Sublocade in th mended 7 days	plicabl e past? s of a bu	e clinical chart n NO YES - uprenorphine-conta	otes Date of Last Injec	tion:
CLINICAL INFORMATION Has the patient been treated Has the patient received the	- pleas I with S recom alent o	se include ap Sublocade in th mended 7 days	plicable past? s of a but of trans	e clinical chart n NO YES - uprenorphine-conta	otes Date of Last Injectaining phine?	NO YES
CLINICAL INFORMATION Has the patient been treated Has the patient received the product delivering the equiv	- pleas I with S recom alent o	se include ap Sublocade in th mended 7 days	plicable past? s of a but of trans	e clinical chart no NO YES - Suprenorphine-contamucosal buprenorphine	otes Date of Last Injectaining phine?	NO YES
CLINICAL INFORMATION Has the patient been treated Has the patient received the product delivering the equiv Current Buprenorphine Product	- plea: I with S recom alent o	se include ap Sublocade in th mended 7 days f 8-24 mg/day (plicable past? s of a but of trans	e clinical chart no NO YES - Suprenorphine-contamucosal buprenorphine	otes Date of Last Injectaining ohine? Dose & Frequence	NO YES
CLINICAL INFORMATION Has the patient been treated Has the patient received the product delivering the equiv Current Buprenorphine Product Allergies:	- please with Some recompliant of the second	se include ap Sublocade in th mended 7 days f 8-24 mg/day (plicable past? s of a buof trans	e clinical chart no NO YES - Suprenorphine-contamucosal buprenorphine ent Buprenorphine	otes Date of Last Injectaining ohine? Dose & Frequence on Date:	NO YES
CLINICAL INFORMATION Has the patient been treated Has the patient received the product delivering the equiv Current Buprenorphine Product Allergies: Baseline LFTs (AST/ALT) if available and the product delivering the equivocal	- please with Some recommend of the second s	se include ap Sublocade in the mended 7 days f 8-24 mg/day of Include update	plicable past? s of a buof trans Curre	e clinical chart not not not not not not not not not no	otes Date of Last Injectaining ohine? Dose & Frequence on Date:	NO YES

PRESCRIPTION INFORMATION

Please send an electronic prescription to UPMC Forbes Pharmacy (3501 Forbes Ave, Oxford Buillding, Room 756)

The recommended dose of SUBLOCADE is 300 mg SQ initially at Months 1 & 2, followed by 100 mg monthly maintenance doses. Increasing the maintenance dose to 300 mg monthly may be considered for patients in which the benefits outweigh the risks. For patients who achieve symptom control on lower doses of oral BUP (8-18 mg/day), 100 mg can be used for the second initiation dose Please see the SUBLOCADE Full Prescribing Information, including Boxed Warning, at sublocadehcp.com

- For abdominal subcutaneous injection only. Do not administer intravenously or intramuscularly.
- · Examine the injection site for signs of infection or evidence of tampering or attempts to remove the depot.
- Prescription use of this product is limited by the Drug Addiction Treatment Act (DATA) to prescribers who are authorized to treat opioid dependence and are DATA 2000 waivered.
- Sublocade may only be delivered to a healthcare setting and is NEVER dispensed to a patient directly
 Serious harm or death could result if administered intravenously. SUBLOCADE forms a solid mass upon contact with body fluids and may cause occlusion, local tissue damage and thrombo-embolic events, including life-threatening pulmonary emboli, if administered intravenously
- Because of the risk of serious harm or death that could result from intravenous self-administration, SUBLOCADE is only available through a restricted program called the SUBLOCADE REMS Program. Healthcare settings and pharmacies that order and dispense SUBLOCADE must be certified in this program and comply with the REMS requirements.